Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 Effects of HMG-CoA reductase inhibitors

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors

GTS-21 bound to human α4β2 nAChR (Ki=20 nM) 100-fold more potently than to humanα7-nAChR

brasofensine

ip once daily for 1 month) inhibits the growth of Apc mutation-driven tumors

1158/0008-5472

Azilsartan (medoxomil) - CAS# 863031-21-4 L 13-27 Effects of HMG-CoA reductase inhibitorsAzilsartan medoxomil also known as TAK 491, is an orally administered angiotensin II receptor type 1 antagonist (blocker) used in the treatment of adults with essential hypertension. Azilsartan medoxomil is a useful and attractive new option for lowering BP in patients with essential hypertension, particularly for those not able to tolerate other antihypertensive drugs. Further studies are required to evaluate the effects of azilsartan medoxomil on